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Urinary excretion of C5b-9 reflects disease activity in passive Heymann
nephritis. Passive Heymann nephritis (PHN) is a model of membranous
nephropathy in rats in which glomerular injury is mediated by the
terminal C5b-9 membrane attack complex of complement. This model
has been shown to be associated with markedly elevated urinary
excretion of C5b-9, compared to other experimental models of glomer-
ulonephritis. To determine if urinary C5b-9 excretion could serve as an
index of disease activity by correlating with the formation and quantity
of glomerular subepithelial immune deposits in PHN, we measured
urinary excretion of C5b-9 in PHN under several experimental condi-
tions. In the heterologous phase a direct correlation was demonstrated
between levels of urinary C5b-9 excretion and the amount of anti-Fx IA
IgG deposited in glomeruli (r = 0.85). In the autologous phase, C5b-9
excretion correlated with the amount of deposit forming antibody
present in the serum and resolved when antibody disappeared, despite
persistence of glomerular deposits of antigen, antibody, C5b-9 and
heavy proteinuria. Glomerular C3 deposits paralleled urinary C5b-9
excretion. Re-initiation of active deposit formation by a second injec-
tion of anti-FxlA produced new C3 deposits and a marked rise in C5b-9
excretion. Finally, complete abrogation of deposit formation by trans-
planting PHN kidneys into normal recipients also halted C5b-9 excre-
tion. Our findings demonstrate that urinary excretion of C5b-9 is a
sensitive index of on-going immunologic disease activity in the PHN
model of membranous nephropathy.
Membranous nephropathy (MN) is the commonest cause of
idiopathic nephrotic syndrome in adults and is characterized by
diffuse glomerular deposits of IgG and C3 in a subepithelial
distribution [1]. The clinical course is quite variable with
fluctuating amounts of proteinuria and an uncertain prognosis,
both with respect to persistence of proteinuria and deterioration
of renal function [21. Multiple treatment protocols aimed at
ameliorating the immune process which presumably underlies
MN, usually employing steroids and/or cytotoxic agents [3, 4],
have attempted to document beneficial effects of therapy using
proteinuria and level of renal function as end points. However,
since the putative pathogenic antibody in MN has not been
identified, no data establishing any direct relationship between
the immune disease mechanism and its consequences such as
proteinuria and loss of renal function have been provided. In
fact, studies of experimental MN [5, 6], as well as biopsy
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studies of patients with drug induced MN [7—9], suggest that
proteinuria may persist long after activity of the disease process
has subsided. Likewise, it is unclear whether the progressive
deterioration of renal function and consequent sclerosis some-
times seen in MN result from a severe self-limited initial
immune insult followed by secondary hemodynamic processes,
or represent on-going immunologic disease activity. Thus, some
index of activity of the underlying immune disease process
would be extremely helpful in assessing the need for therapy
with immunosuppressive agents as well as determining the
response to such immunologic manipulation.
Passive Heyrnann nephritis (PHN) is a model of MN in rats
which closely simulates idiopathic MN in man. Because of the
striking clinical, histological and immunopathological similar-
ities, most investigators believe that the disease mechanisms in
PHN and MN are similar [reviewed in 10]. In PHN, subepithe-
hal immune complex formation is initiated by binding of anti-
body to antigen(s) expressed on the membrane of glomerular
epithelial cells [11, 12]. A consequence of in situ formation of
immune complexes on the cell membrane is activation of
complement with formation of C5b-9 complexes which mediate
the increase in glomerular permeability observed [13, 14].
Recently, we reported that the presence of elevated urinary
excretion of C5b-9 distinguishes PHN from other forms of
experimental glomerulonephritis not involving epithelial cell
membrane antigens [15]. The studies reported here extend this
observation to demonstrate that elevated urinary excretion of
C5b-9 correlates directly with the presence and quantity of
on-going glomerular antibody deposition and complement acti-
vation in the PHN model. Thus, increased urinary C5b-9
excretion serves as both a marker for MN induced by antibody
to a glomerular epithelial cell antigen and also as an indicator of
the presence of on-going glomerular immune deposit formation.
Methods
Experimental design
To establish directly the relationship between increased
urinary excretion of C5b-9 and on-going glomerular antibody
deposition in PHN, four separate studies were carried out:
1.) To determine f the amount of urinary C5b-9 excretion in
the urine correlated with the amount of antibody deposited in
glomeruli during the heterologous phase of PHN. To examine
the relationship between subepithehial immune deposit forma-
tion and the urinary excretion of C5b-9 in PHN, we measured
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urinary C5b-9 excretion following incremental doses of l251
labelled sheep anti-Fx1A IgG. Groups containing three male
Sprague-Dawley rats each (Tyler, Bellevue, Washington,
USA), weighing 180 to 200 g, received an i.v. dose of trace-
labelled sheep anti-Fx1A IgG for 1 mg, 2 mg, 4 mg, 8 mg, 15 mg
or 20 mg. Previous experiments had demonstrated that 7 mg or
greater produced proteinuria exceeding 50 mg124 hours by day
five. Rats were placed in metabolic cages for two consecutive
days beginning approximately 24 hours after injection of anti-
Fx1A, and the urine collected was assayed for C5b-9 and
creatinine content. At the termination of the second urine
collection on day three, the quantity of antibody deposited in
glomeruli was measured as described below.
2.) To deter,nine whether urinary c5b-9 excretion correlated
with glomerular antibody deposition during the autologous
phase of PHN. The effect on urinary C5b-9 excretion of rat
anti-sheep IgG binding to sheep anti-Fx1A IgG previously
deposited in glomeruli was assessed. Nine rats received i.v.
injections of 20 mg of sheep anti-FxIA IgG, while nine control
rats received 20 mg of normal sheep IgG. Rats were placed in
metabolic cages every three days, and serial 24-hour urine
determination of C5b-9, protein, and creatinine were made.
Because quantitative measurement of autologous glomerular
antibody deposition is technically difficult [16, 171, we assessed
disease activity in this study by monitoring glomerular deposits
of antigen (sheep IgG), antibody (rat IgG), C3, and C5b-9by IF
in sequential biopsies obtained every third day as well as by
measuring serum levels of rat antibody to sheep IgG by ELISA.
Biopsies of three rats from each group were obtained at each
sampling point, sera and urine were obtained on all rats.
3.) To determine if urinary c5b-9 excretion could be in-
creased by re-initiating active glomerular antibody binding. To
test the hypothesis that re-development of active glomerular
immune deposit formation in animals with PHN that had ceased
excreting C5b-9 would result in another increase in urinary
C5b-9 excretion, and to relate urinary C5b-9 to the quantity of
antibody deposited in glomeruli, rats with established PHN
induced by injection of 20 mg of anti-Fx lA were studied three
weeks later when urinary C5b-9 excretion had decreased to
nearly undetectable levels. Three groups of rats were studied,
including controls (N = 6) injected with 20 mg of normal sheep
IgG that received a second dose of 20 mg of normal sheep IgG
three weeks later, a second control group (N = 6) that initially
received 20 mg of sheep anti-Fx 1 A followed by 20 mg of normal
sheep IgG i.v. three weeks later, and an experimental group (N
6) that received 20mg of anti-Fx1A followed by a second i.v.
injection of 125! anti-Fx1A at three weeks. Before the second
injection in each group, three serial 20-hour urine collections
were obtained for measurement of C5b-9, protein and creati-
nine. Immediately following re-injection of anti-Fx 1 A, another
three serial urine collections were obtained for measurement of
these same parameters. Kidney biopsies were then obtained
and glomerular antibody binding measured as outlined below.
4.) To determine if cessation of glomerular antibody deposi-
tion would abrogate urinary C5b-9 excretion. To test the
hypothesis that the complete cessation of on-going glomerular
antibody deposition would result in disappearance of C5b-9
excretion in the urine, PHN was induced in 250 to 275 g Lewis
rats by the i.v. injection of 15mg of sheep anti-FxlA IgG on two
consecutive days. Twenty-four hour urine collections for CSb-9
and creatinine measurements were obtained on days 3 to 4, 4 to
5 and 5 to 6. On day six after antibody injection, nephritic
kidneys from PHN rats (N = 3) were transplanted into a
bilaterally nephrectomized normal Lewis rats. In one control
group, a PHN kidney was transplanted into a bilaterally ne-
phrectomized recipient (N 3) that had PHN induced at the
same time as the disease was induced in the donor. A second
control group of PHN rats (N = 4) underwent unilateral
nephrectomy on day six to exclude any effect of uninephrect-
omy alone on C5b-9excretion.
Experimental details
Induction of PHN. In Sprague-Dawley rats, PHN was in-
duced by the i.v. injection of a single dose of the IgG fraction of
sheep anti-FxlA prepared as described in detail elsewhere [6].
In Lewis rats the antibody was injected i.v. on two consecutive
days. For glomerular antibody binding studies, anti-Fx 1 A IgG
was trace-labelled with 1251 using the chloramine I method as
modified by McConahey and Dixon [18].
Measurement of urinary c5b-9 excretion. All urine speci-
mens were collected in 10% (vol/vol) buffer containing a mix-
ture of protease inhibitors including 10 mri benzamidine (Sigma
Chemical Co., St. Louis, Missouri, USA), 10 m epsilon-
aminocaproic acid (Sigma), 20 mii EDTA and 100 kallikrein
inhibitor U/ml of aprotinin (Sigma). Detection of C5b-9 was
performed by an enzyme linked immunoabsorbent assay
(ELISA) that utilized two mouse monoclonal antibodies to a
neoantigen of C5b-9 (2A1), and to C6 (3G11) which were raised,
purified and characterized as described elsewhere [15]. Briefly,
monoclonal antibodies were identified by their reactivity with
rat EDTA-plasma and zymosan-activated rat serum separated
by SDS-PAGE. Antibodies to human complement components
which demonstrated cross reactivity with rat proteins were
used as references [15]. 3G11 identified the same protein in
EDTA-plasma as did the antibody to human C6, as well as a
second high molecular weight band in zymosan activated se-
rum, presumably representing the C5b-9 complex of comple-
ment. 2A1 reacted intensely with this same high molecular
weight component in zymosan activated serum, but failed to
react with EDTA-plasma and therefore presumably represents
antibody to a C5b-9 neoantigen [15].
Microtitration plates (NUNC, Roskilda, Denmark) were
coated with 4 g/welI 2A1 in carbonate buffer. After blocking
with 0.05% casein (Sigma) in PBS serial dilutions of urine
samples were incubated in wells overnight at 4°C. After wash-
ing with phosphate buffered saline, pH 7.2 (PBS)-0.05% Tween
20 (Sigma), biotinylated 3G 11, 400 ng/well, was added for two
hours, followed after washing by horseradish peroxidase cou-
pled to strepavidin (Amersham, Arlington Heights, Illinois,
USA). After one hour of incubation, the wells were again
washed, followed by addition of 100 s1 of solutions containing
0.2 mrvi 2.2'-azine-di-(3-athyl-benythia-zolinesulfonate) (ABTS,
Boehringer Mannheim, Indianapolis, Indiana, USA) and 3.0
mM H-,O, in 100 m acetate buffer at pH 5.0. The extinction at
405 nm was read after 30 minutes at room temperature using
Dynatech MRS6O microtiterplate reader (Dynatech). C5b-9
units were calculated using a previously defined, zyinosan-
activated rat serum reference standard [15].
Measurement of rat antibody to normal sheep IgG (NSIGG).
All plasma samples were obtained through tail vein bleeds in
10% (vol/vol) 0.4 M EDTA. Antibody levels were measured by
an ELISA utilizing NSIGG as both a coating and detecting
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antigen. Microtitration plates (NUNC) were coated with 200 ngl
well NSIGG in carbonate buffer. After blocking with 0.05%
casein (Sigma) in PBS, serial dilutions of plasma samples were
incubated in wells overnight at 4°C. After washing with PBS-
0.05% Tween 20 (Sigma), 1.5 jig/well NSIGG biotinylated as
previously described [151 was added for two hours, followed
after washing by horseradish peroxidase coupled to avidin D
(Vector, Burlingame, California, USA). After one hour of
incubation, the wells were again washed, followed by addition
of 100 jil of solution containing 0.2 mrvi ABTS and 3.0 mi H202
in 100 m acetate buffer at pH 5.0. The extinction at 405 mm
was read at 10 minutes using a Dynatech MR560 microtiterplate
reader. Rat IgG antibody to sheep IgG served as a standard.
Glomerular antibody binding. Determination of glomerular
antibody binding was performed as previously described [6].
Rats anesthetized with chioral hydrate had kidneys perfused
with 60 mIs of PBS in a retrograde fashion through the cannu-
lated superior mesenteric artery to displace any retained blood
prior to sacrifice. Cortical tissue was minced and passed
through a no. 140 and no. 80 brass sieve. Glomeruli trapped on
a no. 200 sieve were suspended in 5 ml of PBS-Tween.
Identification and quantitation was based on light microscopic
evaluation of five 25 jil samples placed on a Fuchs Rosenthal
hemocytometer, with a total volume evaluated of 6.4 jil per
sample. Gamma emission was then quantitated on the pelleted
samples. Antibody bound to glomeruli was quantitated based
on the specific activity of the injected antibody, the ratio of
labeled to unlabeled antibody, and the gamma emission per
isolated glomeruli.
Renal transplantation. All transplants were carried out in
syngeneic Lewis rats. The left kidney was harvested using
aseptic technique following induction of anesthesia with chloral
hydrate. A cuff of vena cava and a segment of aorta were
included to facilitate the vascular anastomoses. A generous
length of ureter was obtained for direct implantation into the
recipient bladder. The kidney was flushed in situ with 4°C
normal saline containing lidocaine, 0.1 rng/ml and heparin, 10
U/mI. Topical papaverine was applied to the renal artery to
prevent spasm. The kidney was stored on ice until the recipient
was prepared. Preparation consisted of bilateral native nephrec-
tomy, and a length of vena cava and aorta inferior to the native
renal vessels were dissected free. End-to-side vascular anasto-
moses were performed using 10-0 monofilament nylon using the
micro-surgical technique of Silber and Crudop [19] followed by
ureterocystostomy. Recipients that exhibited gross hematuria
or became oliguric (< 2 cc/24 hr) or anuric during the study
period beginning 24 hours after transplant were excluded from
the study.
Immunofluorescent (IF) studies. All renal biopsies of native
kidneys were done under ether anesthesia, via a lateral flank
incision. Biopsies obtained after transplantation were done
under chloral hydrate anesthesia via a midline abdominal inci-
sion. Hemostasis was achieved with gelfoam (Upjohn, Kalama-
zoo, Michigan, USA). The tissue was flash frozen in dry
ice-isopentane, and stored at —70°C until processed. Cryostat
sections were cut, stained and studied with the fluorescein-
conjugated IgG fractions of monospecific antisera to sheep IgG,
rat IgG, and rat C3 (Cappel Laboratories, Inc., Cochraneville,
Pennsylvania, USA) as described elsewhere [5]. Indirect IF for
rat C5b-9 was performed by incubating tissue with an appropri-
ate dilution of biotinylated 2Al for 60 minutes followed by
staining with fluorescein conjugated strepavidin (Amersham).
The intensity of fluorescence was evaluated semiquantitatively
as follows: 0, indistinguishable from control; trace, barely
detectable; 1+, present but faint; 2+, definite; 3+, strongly
positive; 4+, maximally positive.
Urine collections. All urine samples were obtained by placing
rats in metabolic cages with free access to water but not food.
Where consecutive daily urines were collected, rats were
removed from the cage for four hours with free access to food
and water daily prior to initiating the next collection period.
Miscellaneous measurements. Urine creatinine measure-
ments were made using the picric acid method as described in
detail elsewhere [20]. Urine protein excretion was measured by
a sulfosalicylic acid method [211 using a whole serum standard
(Lab. Trol., Dade Diagnostics, Aquado, Puerto Rico, USA).
Statistical analysis
Correlation of glomerular antibody binding with urinary
CSb-9 excretion was performed using exponential regression
[22]. All results of urine C5b-9/creatinine determinations and
24-hour urinary protein excretions are expressed as mean
standard error. Differences between groups were analyzed
using the Student's t-test where parametric relationships ex-
isted. Non-parametric data were analyzed using the Mann-
Whitney test. P values <0.05 are regarded as significant.
Results
The quantity of glomerular antibody deposited correlates
directly with the amount of urinary C5b-9 excretion during
the heterologous phase of PHN
To establish the relationship between the quantity of anti-
Fx1A IgG bound in glomeruli during the heterologous phase of
PHN and the amount of C5b-9 excreted in the urine, doses of
125! anti-FxIA IgG were administered which resulted in a range
of antibody bound 72 hours later from 1.5 to 17.1 jig/76,000
glomeruli at 72 hours. Immunofluorescence studies performed
on day 3 after injection on animals given equivalent doses of
cold antibody demonstrated glomerular staining for sheep IgG
and rat C3 and C5b-9 with only trace staining for rat IgG. No
tubular brush border staining for sheep IgG or rat C5b-9 was
detected. Measurements of urinary C5b-9 excretion from 24 to
72 hours demonstrated a strong direct correlation between the
amount of 1251 IgG deposited in glomeruli and the two-day total
urinary excretion of C5b-9 corrected for creatinine excretion
(Fig. 1). All animals that received radiolabeled antibody had
measurable deposits of antibody in the kidney. Animals that
received doses too small to induce proteinuria (< 7 mg) all
excreted C5b-9. Thus, urinary C5b-9 excretion correlated well
with glomerular antibody binding even in the absence of detect-
able increases in urinary protein excretion.
Urinary C5b-9 excretion correlates with anri-IgG deposition
during the autologous phase of PHN
The relationship between IF deposits of sheep IgG, rat IgG,
C3 and C5b-9 as well as circulating levels of rat anti-sheep IgG,
urinary protein excretion and urinary C5b-9 excretion in the
autologous phase of PHN are presented in Figure 2. Staining for
sheep IgG was maximal by day three and persisted unchanged
for three weeks (Fig. 2A). Rat IgG staining was maximal by day
nine and also persisted (Fig. 2A) as did glomerular deposits of
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Sheep lgGand Rat IgGo Staining1fl1flifl
C3 and C5b-90 Staining
Time, days
Fig. 2. Time course of glomerular deposits of sheep lgG and rat JgG
(A), rat C3 and C5b-9 (B) and rat anti-sheep IgG levels, urinary protein
excretion, and urinary C5b-9 excretion during the autologous phase of
PHN. Urinary C5b-9 excretion parallels rat anti-sheep IgG levels and
glomerular C3 deposits, while deposits of rat and sheep IgG, rat C5b-9
and proteinuria persist. Symbols in C are: (•) urinary C5b-9; (0)
urinary protein; (U) serum anti-SIgG concentration.
C5b-9 (Fig. 2B). Proteinuria was present at three days, in-
creased on day six, was maximal at day nine and persisted
relatively unchanged through 21 days (Fig. 2C). In contrast,
C5b-9 excretion peaked at day six and then diminished to
normal levels by day 18 despite persistent proteinuria (Fig. 2C).
Plasma antibody titers against sheep IgG given on day 0 were
almost uniformly undetectable by day 3, were maximal on day
6 and then gradually decreased to undetectable levels again by
Gab
Dose N Kidney .tg antibody % Bound
15 mg 3 naive 8.660 0.897 0.058 0.006
20 mg 3 naive 13.769 0.944 0.068 0.015
20mg 6 autologous
PHN
201.500 23.561 1,008 0.118
Urinary C5b-9 excretion correlates with the amount of
antibody deposited in glomeruli after a second injection of
anti-FxIA
To further document the relationship between urinary C5b-9
excretion and active glomerular antibody deposition, rats in the
autologous phase of PHN at three weeks in which urinary C5b-9
excretion had returned to normal values and glomerular C3
immunofluorescence had become negative were re-injected
with anti-Fx IA. A prompt increase in urinary C5b-9 excretion
occurred with redevelopment of glomerular C3 deposition (Fig.
3). As in the initial heterologous phase, the amount of C5b-9
excreted again correlated with the quantity of IgG bound in
glomeruli 72 hours after injection. The quantity of anti-Fx1A
antibody bound correlated directly on an exponential scale with
urinary excretion of C5b-9 as described by the equation y =
0.022 e22302 X; r = 0.82; P <0.025. As compared to glomerular
binding of anti-FxIA IgG in naive kidneys at 72 hours, which
varied from 0.05 to 0.29% of the initially injected dose, the
anti-Fx1A IgG bound to autologous phase PHN kidneys 72
hours after second injection was increased, ranging from 0.91 to
1.20% of injected dose (Table 1).
Urinary C5b-9 excretion ceases when glomerular antibody
deposition stops
To further demonstrate that on-going glomerular immune
deposit formation is required for increased urinary C5b-9 ex-
cretion, kidneys of rats with PHN were removed at day six
when heterologous anti-Fx1A antibody deposition was on-
going, and urinary C5b-9 excretion was elevated, and were
transplanted into nephrectomized normal recipients. With re-
moval of kidneys from a nephritogenic environment, urinary
C5b-9 excretion promptly ceased (Fig. 4). In contrast, kidneys
placed in recipient rats that had earlier received the same
injection of anti-FxIA given to donors continued to excrete
C5b-9 in the urine at levels identical to those in uninephrecto-
mized donors (Fig. 4). In the normal recipients of PHN kidneys,
C5b-9 excretion again increased five days after transplantation
coincident with the appearance of glomerular deposits of rat
0.60
0.50
a
. 0.40
0.30
0)
U)o 0.20
Table 1. Glomerular binding of anti-Fxla antibody (Gab) in naive
and autologous phase PHN kidneys 72 hours after injection
0
0 2 4
All values are mean SE. N = number of rats.
a i <.01
day 18, suggesting that urinary C5b-9 excretion reflected autol-
ogous phase disease activity induced by rat IgG antibody
binding to planted sheep IgG antigen. Of interest, although
deposits of antigen, antibody and C5b-9 persisted indepen-
dently of apparent on-going immune deposit formation, glomer-
ular deposits of C3 diminished (Fig. 2B) in parallel with urinary
C5b-9 excretion (Fig. 2C).
6 8 10 12 14 16 18 Control rats injected with equivalent doses of normal sheepIgG, remained normal with respect to all parameters measured.g ab/two kidneys
Fig. 1. Relationship between glomerular antibody binding of anti-
FxIA (72 hours) and urinary excretion of C5b-9 in 18 rats. The quantity
ofanti-FxIAantibody bound correlated directly on an exponential scale
with urinary excretion of C5b-9 as described by the equation y 0.906
e'275 X; r = 0.88; P < 0.0005. Each point represents data from one rat.
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Fig. 3. Effect of a second injection of anti-
FxIa and normal sheep IgG on: a.
glomerular C3 deposition, and b. urinary
excretion of C5b-9.
sufficient to induce proteinuria. Moreover, C5b-9 excretion
ceases as soon as antibody deposition is terminated, as evi-
denced both by termination of the autologous phase as well as
the transplantation experiments. Previous studies have shown
that the C5b-9 in the urine does not result from glomerular
filtration of circulating C5b-9 complexes [15]. Moreover, the
absence of detectable C5b-9 formation on proximal tubular
brush borders, the onset of increased urinary C5b-9 excretion
before proteinuria occurred, and the presence of increased
C5b-9 excretion following deposition of quantities of antibody
insufficient to cause proteinuria all suggest that the urinary
C5b-9 complexes measured are of glomerular rather than tubu-
lar origin. However, the inducing antibody is reactive with
tubular brush border, and some contribution of rapidly shed
C5b-9 complexes formed on proximal tubular brush border
cannot be excluded.
Of interest, our data also clearly demonstrate that urinary
C5b-9 excretion coincides in time with the onset of antibody
deposition during the autologous phase and correlates directly
with the amount of antibody deposited, although the antibody in
this phase is binding to exogenous antigen previously localized
on the glomerular epithelial cell membrane or perhaps shed in a
subepithelial distribution. Previous studies suggest that media-
tion of glomerular injury in this phase of disease is also C5b-9
dependent [14, 23, 24]. Moreover, increased C5b-9 excretion
remains present in the autologous phase as long as antibody to
sheep IgG is present in plasma and therefore presumably as
long as deposit formation in glomeruli is on-going. The obser-
vation that urinary C5b-9 excretion in the autologous phase
resolves by day 18, correlating in time with the disappearance
of circulating antibody, suggests that deposit formation is
self-limited despite the persistence of proteinuria. Clearly in
this setting, urinary C5b-9 excretion served as a much more
C3 0 and C5b-9 0 Staining in Experimental Group
n ñ
C3 D and C5b-9 0 Staining in Control Group
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Rein Jection
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Time, days
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. 0.50
0.40
0.30
0.200
0.10
0
0 3 4 5 6 7 8 9 10 11
Time, days
Fig. 4. Effect of transplantation to a benign immunologic mi!eau, N =
3 (•), transplantation to an identical immunologic mi!eau N = 3 (0),
and uninephrectomy N = 4 (El) on urinary excretion of C5b-9 in PHN.
IgG and therefore the onset of autologous phase antibody
deposition (data not shown). Nephrectomized rats that received
normal kidneys did not develop detectable urinary C5b-9 ex-
cretion (data not shown).
Discussion
Our studies confirm in several settings the suggestion from
earlier work that urinary excretion of CSb-9 complexes reflects
active immune deposit formation in glomeruli in a model of
membranous nephropathy where these deposits result from
antibody binding to a glomerular epithelial cell antigen [15].
When deposits are formed by this mechanism, the quantity of
C5b-9 excreted was closely related to the quantity of antibody
deposited regardless of whether that amount of antibody was
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sensitive indicator of disease activity than did glomerular de-
posits of antigen, antibody or proteinuria.
A related observation of some interest is that glomerular
staining for C3 paralleled urinary C5b-9 excretion, suggesting
that it too may represent an index of on-going disease activity.
Thus C3 staining was present in the heterologous and early
autologous phase of the disease, disappeared by day 18, and
reappeared when passive administration of anti-FxZA re-initi-
ated disease with increased urinary C5b-9 excretion. C3 stain-
ing also disappeared within three days in the PHN kidneys
transplanted into normal hosts. Observations of others in ani-
mals with glomerular C3 deposits suggest that C3 antigen is
rapidly cleared when complement depletion is induced with
cobra venom factor [25]. Thus the presence of C3 staining by IF
suggests active on-going deposit formation and correlates with
urinary C5b-9 excretion. Observations of C3 disappearance late
in the course of autologous immune complex nephritis, there-
fore, suggest the cessation of the immunologic process late in
that disease [26, 27]. Similarly in human membranous nephrop-
athy, reports of wide variability in C3 presence and intensity
[28—30] may likewise connote presence or absence of an on-
going immunologic process.
An unrelated observation deserving comment relates to the
marked differences in deposition ofanti-FxlA antibody in naive
glomeruli versus autologous phase PHN glomeruli (Table 1).
This 10- to 15-fold difference in binding could simply reflect the
decreased barrier to filtration in the latter glomeruli, allowing
more sheep IgG to penetrate the glomerular basement mem-
brane and bind to the antigenic sites on the epithelial cell. An
alternative hypothesis would be that the increase in antibody
binding reflects up regulation of epithelial cell production of cell
membrane antigen. Our data do not permit distinction between
these possibilities.
The mechanism of urinary C5b-9 excretion in PHN has not
been fully elucidated. Our previous studies suggest it occurs
only when glomerular epithelial cell membrane insertion of
C5b-9 occurs and that this phenomenon is prominent when
subepithelial deposits form by antibody binding to a cell mem-
brane antigen, but is absent or undetectable when deposits form
by other mechanisms or at other sites [IS]. Our current study
also demonstrates that this phenomenon occurs when an anti-
body binds to a previously localized antibody on the surface of
the epithelial cell. The studies of Kerjaschki and Farquhar and
others suggest that the antigen is primarily GP330 [11, 12].
Recent immunoultrastructural studies demonstrate that the
C5b-9 is inserted into the membrane of the glomerular epithelial
cell in the region of the clathrin coated pits where deposit
formation is initiated, and that it is endocytosed and transported
in multi-vesicular bodies through the epithelial cell to be exocy-
tosed into the urinary space [31]. This process appears to
involve only C5b-9 and not antigen, antibody or C3 which are
patched, capped and shed from the cell surface to form subepi-
thelial immune complex deposits [32—34]. Thus the urinary
excretion of C5b-9 appears to represent membrane insertion of
the active complement complex whereas immune deposits not
formed on the membrane surface appear to contain predomi-
nantly inactive S protein containing C5b-9 which cannot insert
into cell membranes [31, 35]. An alternative explanation would
be that the clathrin coated pit may contain vitronectin receptors
for SC5b-9 that result in internalization and transcellular pas-
sage with subsequent exocytosis of the complexes [311.
The relationship between the epithelial cell processing of
C5b-9 and the loss of glomerular barrier function leading to
proteinuria and nephrotic syndrome is unclear. We and others
have postulated that membrane inserted CSb-9 induces a subly-
tic effect on the cell leading to metabolic changes that ultimately
result in loss of basement membrane functional integrity [14,
361. Evidence supporting this concept includes the absence of
apparent epithelial cell death in human and experimental mem-
branous nephropathy as well as studies showing altered calcium
influx [37, 381, increases in cAMP [37], stimulation of phospho-
lipases [381, and altered type IV collagen production by glomer-
ular epithelial cells exposed to C5b-9 in culture [39]. Glomerular
mesangial cells exposed to sublytic concentrations of C5b-9
exhibit increased production of interleukin I [40] and reactive
oxygen species [41]. However, the exact relationship of these
cellular events to the alteration in glomerular permeability in
this disease remains undefined.
The most important implication of our studies is the possibil-
ity that measurement of C5b-9 in human membranous nephrop-
athy might produce information on the possible role of autoim-
mune mechanisms in the human disease as well as provide a
non-invasive index of on-going disease activity. Experimental
studies suggest that once the filtration barrier is lost in this
disease, proteinuria may persist for extended periods of time in
the absence of on-going deposit formation in the kidney [42].
Data from patients with drug-induced membranous nephrop-
athy and membranous nephropathy in renal allografts suggest
that the pathophysiology of the human lesion is similar [7—9, 43,
441. While some controlled studies show benefit from steroid
and immunosuppressive drug therapy in membranous nephrop-
athy [3, 4], documentation of this benefit is complicated by the
variable course of the disease, its indolent nature and the fact
that no evidence of disease activity other than proteinuria and
loss of renal function is available. It seems almost certain that
significant numbers of patients are being treated with poten-
tially toxic agents in the absence of any active on-going immune
disease process. Our results provide a rationale for more
definitive studies of the possibility that glomerular C3 deposits
may also provide a helpful index of disease activity at the time
of biopsy. If similar mechanisms are operative in human mem-
branous nephropathy as recent data suggest [45], then both
glomerular C3 staining, and urinary C5b-9 excretion could serve
as indices of activity of the underlying immunologic disease.
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